Tibial Lead Levels and Erythropoiesis Stimulating Agent Dosing Among 75 Patients with End-Stage Kidney Disease
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Danziger J, Mukamal K, Weinhandl E
. Associations of Community Water Lead Concentrations with Hemoglobin Concentrations and Erythropoietin-Stimulating Agent Use among Patients with Advanced CKD. J Am Soc Nephrol. 2021; 32(10):2425-2434.
PMC: 8722797.
DOI: 10.1681/ASN.2020091281.
View
2.
Specht A, Dickerson A, Weisskopf M
. Comparison of bone lead measured via portable x-ray fluorescence across and within bones. Environ Res. 2019; 172:273-278.
PMC: 6511307.
DOI: 10.1016/j.envres.2019.02.031.
View
3.
Paudel S, Geetha P, Kyriazis P, Specht A, Hu H, Danziger J
. Association of environmental lead toxicity and hematologic outcomes in patients with advanced kidney disease. Nephrol Dial Transplant. 2022; 38(5):1337-1339.
PMC: 10362492.
DOI: 10.1093/ndt/gfac336.
View
4.
Harari F, Sallsten G, Christensson A, Petkovic M, Hedblad B, Forsgard N
. Blood Lead Levels and Decreased Kidney Function in a Population-Based Cohort. Am J Kidney Dis. 2018; 72(3):381-389.
DOI: 10.1053/j.ajkd.2018.02.358.
View
5.
Gauthier-Loiselle M, Michalopoulos S, Cloutier M, Serra E, Bungay R, Szabo E
. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective. J Manag Care Spec Pharm. 2021; 27(12):1703-1713.
PMC: 10391171.
DOI: 10.18553/jmcp.2021.27.12.1703.
View